olanzapine + risperidone
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Bipolar Disorder
Conditions
Bipolar Disorder
Trial Timeline
Aug 1, 2001 → Aug 1, 2002
NCT ID
NCT00034580About olanzapine + risperidone
olanzapine + risperidone is a approved stage product being developed by Eli Lilly for Bipolar Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00034580. Target conditions include Bipolar Disorder.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00190749 | Approved | Completed |
| NCT00034580 | Approved | Completed |
Competing Products
20 competing products in Bipolar Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Olanzapine | Eli Lilly | Phase 3 | 77 |
| Valproate + Lithium + Risperidone + Olanzapine | Eli Lilly | Phase 3 | 77 |
| Olanzapine + Placebo | Eli Lilly | Approved | 85 |
| FK949E | Astellas Pharma | Phase 3 | 77 |
| FK949E | Astellas Pharma | Phase 3 | 77 |
| FK949E + Placebo | Astellas Pharma | Phase 2/3 | 65 |
| Escitalopram + Bupropion XL | Lupin Limited | Phase 3 | 77 |
| Olanzapine | Eli Lilly | Approved | 85 |
| Olanzapine Hydrochloride + Lithium Carbonate | Eli Lilly | Phase 3 | 77 |
| olanzapine + lithium + valproate + carbamazepine | Eli Lilly | Phase 3 | 77 |
| Olanzapine | Eli Lilly | Approved | 85 |
| Olanzapine | Eli Lilly | Phase 3 | 77 |
| LY2979165 + Placebo | Eli Lilly | Phase 1 | 33 |
| olanzapine + divalproex sodium + placebo | Eli Lilly | Approved | 85 |
| LY2979165 + placebo | Eli Lilly | Phase 1 | 33 |
| Topiramate + Placebo | Eli Lilly | Approved | 85 |
| olanzapine | Eli Lilly | Phase 3 | 77 |
| Olanzapine + Placebo | Eli Lilly | Phase 3 | 77 |
| Brenipatide + Placebo | Eli Lilly | Phase 2 | 52 |
| Olanzapine Fluoxetine Combination (OFC) + Placebo | Eli Lilly | Approved | 85 |